Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (3.969.936 €): ALTERSBEDINGTE VERÄNDERUNGEN DER HÄMATOPOESE Hor01.06.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
ALTERSBEDINGTE VERÄNDERUNGEN DER HÄMATOPOESE
ARCH is a network of highly qualified experts in experimental hematology created to decipher the causal relationship between the physiological changes in the hematopoietic system during lifespan and the parallel occurrence of specific age-related hematological diseases (pediatric, adult, elderly), with the aim to develop novel targeted therapeutic treatments. ARCH research will integrate the results from complementary model systems (cell lines, mouse models, cells from leukemia patients) and it will deploy a large panel of cutting-edge technologies, such as single cells genomics, epigenomics, genome editing and organoid cultures, in a multi-faceted effort. The ARCH ambitious goal requires scientific and financial resources beyond the capability of a single group. To reach this goal, the ARCH network brings together 15 beneficiaries (12 academic, 2 SMEs and 1 private research institute) and 5 Partner organisations (3 academic, 1 SME and 1 patients’ association). Two European Consortia are present through their italian nodes. ARCH will recruit 15 ESRs that will be all enrolled in PhD programmes. Besides research laboratory work, the ARCH training programme includes scientific, technical and transferable skills courses that will provide ESRs with a solid scientific culture and with awareness of responsible research and innovation issues. This broad portfolio will enable ESRs to become leading academic, clinic or industrial players in the field. The unique combination of scientific excellence, quality of the educational programme and experience in translating basic research into exploitable results will provide ARCH with the real possibility of positively contributing to the enhancement of European competitiveness in the development of innovative, targeted drugs/treatments for hematological diseases, which currently represent a serious socio-economical problem for the European health care system.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| ? | |
| Academisch Ziekenhuis Groningen | 265.620 € |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | 250.905 € |
| Centre Europeen de Recherche en Biologie et Medecine | 274.802 € |
| Diagenode | 256.320 € |
| 261.500 € | |
| 261.500 € | |
| 243.018 € | |
| Institut Curie | 274.802 € |
| Institut National de la Sante et de la Recherche Medicale | 274.802 € |
| King's College London | 303.173 € |
| MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN e. V. | 252.788 € |
| 263.501 € | |
| Universita Degli Studi DI Roma LA Sapienza | 261.500 € |
| Universita' Degli Studi DI Milano-Bicocca | 261.500 € |
| Veterinaermedizinische Universitaet Wien | 264.207 € |
Quelle: https://cordis.europa.eu/project/id/813091
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: Becton Dickinson Italia S.p.A., Castano Primo, Italien.
Die Visualisierungen zu "Becton Dickinson Italia S.p.A. - EU-Förderung (3.969.936 €): ALTERSBEDINGTE VERÄNDERUNGEN DER HÄMATOPOESE"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
